Roth Capital steps to the sidelines on Peregrine Pharmaceuticals (PPHM -79%), downgrading it to Neutral and removing it from its Focus List due to the uncertainty over the discrepancies in its Phase II study of bavituximab. The firm also skewered its price target on the shares, slashing it to $0.70 from $9.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Dec 31, 2014)
at MarketWatch.com (Jul 14, 2014)
at CNBC.com (Jul 14, 2014)
at CNBC.com (Jul 11, 2013)
at CNBC.com (Mar 12, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs